ComptonWM, HanB, HughesA, et al.Use of marijuana for medical purposes among adults in the United States. JAMA. 2017; 317(2):209–11.
3.
PergamSA, WoodfieldMC, LeeCM, et al.Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer. 2017; 123(22):4488–97.
4.
CerdáM, WallM, KeyesKM, et al.Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend. 2012; 120(1–3):22–7.
5.
WangJB, RamoDE, LishaNE, CataldoJK. Medical marijuana legalization and cigarette and marijuana co-use in adolescents and adults. Drug Alcohol Depend. 2016; 166:32–8.
6.
AsvatY, KingAC, SmithLJ, et al.Substance use behaviors in adolescent and young adult cancer patients: associations with mental and physical health. Psychooncology. 2020 [Online ahead of print]; DOI: 10.1002/pon.5378.
DonovanKA, Oberoi-JassalR, ChangYD, et al.Cannabis use in young adult cancer patients. J Adolesc Young Adult Oncol. 2020; 9(1):30–5.
9.
Ryan-IbarraS, InduniM, EwingD. Prevalence of medical marijuana use in California, 2012. Drug Alcohol Rev. 2015; 34(2):141–6.
10.
WhitcombB, LutmanC, PearlM, et al.Use of cannabinoids in cancer patients: a Society of Gynecologic Oncology (SGO) clinical practice statement. Gynecol Oncol. 2020; 157(2):307–11.
11.
MartellK, FairchildA, LeGerrierB, et al.Rates of cannabis use in patients with cancer. Curr Oncol. 2018; 25(3):219–25.
12.
EssigS, SteinerC, KuehniCE, WeberH, KissA. Improving communication in adolescent cancer care: a multiperspective study. Pediatr Blood Cancer. 2016; 63(8):1423–30.
13.
DennisM, BaborTF, RoebuckMC, DonaldsonJ. Changing the focus: the case for recognizing and treating cannabis use disorders. Addiction. 2002; 97(Suppl. 1):4–15.
14.
HadlandSE, HarrisSK. Youth marijuana use: state of the science for the practicing clinician. Curr Opin Pediatr. 2014; 26(4):420–7.
15.
HsiaoP, ClavijoRI. Adverse effects of cannabis on male reproduction. Eur Urol Focus. 2018; 4(3):324–8.
16.
MeierMH, CaspiA, AmblerA, et al.Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012; 109(40):E2657–64.
17.
EngelsFK, de JongFA, SparreboomA, et al.Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist. 2007; 12(3):291–300.
18.
BrownJD, WintersteinAG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med. 2019; 8(7):989.
19.
RocqueR, LeanzaY. A systematic review of patients' experiences in communicating with primary care physicians: intercultural encounters and a balance between vulnerability and integrity. PLoS One. 2015; 10(10):e0139577.
20.
AnanthP, MaC, Al-SayeghH, et al.Provider perspectives on use of medical marijuana in children with cancer. Pediatrics. 2018; 141(1):e20170559.
21.
PeachmanRR. Clinicians support medical marijuana use in children with cancer, but lack knowledge. JAMA. 2018; 319(9):852–3.
22.
Hewa-GamageD, BlaschkeS, DrosdowskyA, et al.A cross-sectional survey of health professionals' attitudes toward medicinal cannabis use as part of cancer management. J Law Med. 2019; 26(4):815–24.
23.
Rod RassekhS. Urgent need for “EBMM” in pediatric oncology: evidence based medical marijuana. Pediatr Hematol Oncol. 2019; 36(5):253–4.
24.
BackAL, ArnoldRM, BaileWF, et al.Approaching difficult communication tasks in oncology. CA Cancer J Clin. 2005; 55(3):164–77.
25.
KimB, WhiteK. How can health professionals enhance interpersonal communication with adolescents and young adults to improve health care outcomes?: systematic literature review. Int J Adolesc Youth. 2018; 23(2):198–218.